The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $15.90

Today's change+0.73 +4.81%
Updated July 28 12:38 PM EDT. Delayed by at least 15 minutes.
 

Nektar Therapeutics

Nasdaq: NKTR
Last

(U.S.) $15.90

Today's change+0.73 +4.81%
Updated July 28 12:38 PM EDT. Delayed by at least 15 minutes.

Nektar Therapeutics up sharply

Nektar Therapeutics is up sharply today, rallying (U.S.)$0.73 or 4.81% to (U.S.)$15.90. Over the last five days, shares have gained 3.31%, but are down 5.64% for the last year to date. Shares have outperformed the S&P 500 by 20.15% during the last year.

Key company metrics

  • Open(U.S.) $15.14
  • Previous close(U.S.) $15.17
  • High(U.S.) $15.96
  • Low(U.S.) $15.14
  • Bid / Ask(U.S.) $15.90 / (U.S.) $15.91
  • YTD % change-5.64%
  • Volume1,376,772
  • Average volume (10-day)906,310
  • Average volume (1-month)912,362
  • Average volume (3-month)969,935
  • 52-week range(U.S.) $9.16 to (U.S.) $17.55
  • Beta1.67
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.01
Updated July 28 12:38 PM EDT. Delayed by at least 15 minutes.
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue59396023
Total other revenue--------
Total revenue59396023
Gross profit50315312
Total cost of revenue98711
Total operating expense68836066
Selling / general / administrative10131010
Research & development49474345
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--14----
Other operating expenses, total--------
Operating income-9-430-43
Interest income (expense), net non-operating-11-11-9-9
Gain (loss) on sale of assets--------
Other--------
Income before tax-19-54-8-52
Income after tax-19-54-8-53
Income tax, total0000
Net income-19-54-8-53
Total adjustments to net income--------
Net income before extra. items-19-54-8-53
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-19-54-8-53
Inc. avail. to common incl. extra. items-19-54-8-53
Diluted net income-19-54-8-53
Dilution adjustment0------
Diluted weighted average shares136134133132
Diluted EPS excluding extraordinary itemsvalue per share-0.14-0.40-0.06-0.40
Dividends per sharevalue per share0.00--0.000.00
Diluted normalized EPSvalue per share-0.14-0.34-0.06-0.40